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In mammals, toxic electrolytes of endogenous and exogenous origin are excreted 
through the urine and bile.  Before excretion, these compounds cross numerous 
cellular membranes in a transporter-mediated manner.  However, the protein 
transporters involved in the final excretion step are poorly understood.  Here, we 
show that MATE1, a human and mouse orthologue of the multidrug and toxin 
extrusion (MATE) family conferring multidrug resistance on bacteria, is primarily 
expressed in the kidney and liver, where it is localized to the luminal membranes of 
the urinary tubules and bile canaliculi.  When expressed in HEK293 cells, 
MATE1 mediates H+-coupled electroneutral exchange of tetraethylammonium 
(TEA) and 1-methyl-4-phenylpyridinium (MPP).  Its substrate specificity is 
similar to those of renal and hepatic H+-coupled organic cations (OCs) export.  
Thus, MATE1 appears to be the long searched for polyspecific OC exporter that 
directly transports toxic OCs into urine and bile.  
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Living organisms must deal with environmental toxins, metabolic waste products, and, 
primarily in humans, drugs with extremely diverse structures in order to remain viable.  
In mammals, these toxic organic compounds are mainly excreted through the kidney and 
liver.  Renal excretion involves glomerular filtration and/or tubular secretion.  Toxic 
organic compounds are taken up at the basolateral membranes of tubule cells, followed 
by excretion out of the cells at the brush-border membranes (1-7).  Hepatocytes also 
absorb toxic organic compounds at the sinusoidal membranes and excrete them through 
the bile canaliculi (1-7).  Although it has been concluded from a large number of 
biochemical and physiological studies that a transporter(s) is principally responsible for 
the final step of excretion of organic cations (OCs), its molecular identity remains 
unknown (5-7).  The putative OC exporter mediates electroneutral H+/OCs exchange 
(5-7).  Furthermore, it recognizes a wide variety of OCs including cationic drugs, some 
vitamins and many endogenous compounds such as choline and dopamine and, thus, 
should be regarded as a multidrug or polyspecific exporter (5-7).  We, therefore, 
hypothesized that mammalian orthologue(s) of bacterial multidrug transporters, if any, 
are responsible for the extrusion of OCs.   
       Bacterial multidrug transporters have been classified into several groups, which 
include the major facilitator superfamily (MSF), the small multidrug resistance (SMR) 
family, the resistance nodulation cell division (RND) family, the ATP binding cassette 
(ABC) family, and MATE family (8-10).  Of them, MATE family is the most recently 
classified multidrug resistance-conferring protein family (8-10).  Although the overall 
properties of the MATE family are not elucidated yet, some MATE-type proteins 
mediate H+- or Na+-coupled export of cationic drugs in bacteria (8-10).   
       In the present study, we identify human and mouse MATE orthologues, MATE1 
and MATE2.  We present evidence that MATE1 is predominantly expressed in kidney 
and liver and responsible for the final step of excretion of organic cations (OCs) through 
exchange of protons.  
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Materials and Methods 
cDNAs.  cDNA of human MATE1 (hMATE1: accession number, NP-060712) was 
cloned by RT-PCR from human brain RNA.  After synthesis, the cDNA solution was 
diluted x10 and added to the PCR reaction buffer, which contained 0.6 mM total 
dNTPs (150 µM each dNTP), 25 p mol of each primer and 1.5 units of Ampli 
Taq-Gold DNA polymerase (PerkinElmer).  Amplication was carried out with 35 
temperature cycles consisting of denaturation at 94 oC for 30 sec, annealing at 56 oC 
for 30 sec, and extension at 72 oC for 1 min.  The amplification products (1804 bp) 
were analyzed by agarose gel electrophoresis.  The primers used were based on 
database sequences (Genbank No. AK001709): sense primer, 5’- 
GGCCGGTACCCGCGAGTCACATGGAAGCTC -3’; antisense primer, 5’- 
CACTTCTAGACCTGTGAATTGTGTGTAAGC -3’. The DNA fragment was 
digested with KpnI and XbaI, and then cloned into pBluescriptKS(+).  The sequence 
of hMATE1 was confirmed to be free of errors by comparing it with the human 
genome sequence.  cDNAs of human MATE2 (hMATE2: accession number, 
NP-690872), mouse MATE1 (mMATE1 : accession number, AAH31436) and mouse 
MATE2 (mMATE2 : accession number, XP_354611) were also cloned as above.  
 
Mutagenesis.  Point mutation E273Q was introduced into the wild type hMATE1 by 
means of the overlap extension method employing the following oligonucleotide, 5-’ 
GGCCCACCACTGCATGCACAGCATGAGC -3’, according to the published 
procedure (11). 
 
Northern blot analysis.  Human and mouse multiple-tissue Northern blots (MTN) 
were purchased from Clontech.  For Northern analysis, nucleotide fragments 
encoding the N-terminal region of hMATE1 (nt 10 -601; 592 bp), the C-terminal of 
 5 
hMATE2 (nt 1412 – 1712; 301 bp), the C-terminal of mMATE1 (nt 1336-1599; 264 
bp), and the C-terminal of mMATE2 (nt 1087 – 1648; 562 bp) generated by PCR and 
labeled with 32P-dCTP using DNA labeling kit (Boehringer Mannheim) were used as 
hybridization probes.  Hybridization was performed at 68 oC for 1 h in Express Hyb 
hydridization buffer (Clontech), with washing under high-stringency conditions at 50 
oC. 
 
Antibodies.  Site-specific rabbit (JW) polyclonal antibodies against hMATE1 and 
mMATE1 were prepared by repeated injections of GST-fusion polypeptides encoding 
amino acid residues N461 – R546 of hMATE1 
(NWKKACQQAQVHANLKVNNVPRSGNSALPQDPLHPGCPENLEGILTNDVGK
TGEPQSDQQMRQEEPLPEHPQDGAKLSRKQLVLRR) and amino acid residues 
P495 – Q532 of mMATE1 
(PESHGEIMMTDLEKKRRDSVGPADEPATSFAYPSKGQQ). 
 
Western blot analysis.  Human tissue samples were obtained from CosmoBio.  
Total membrane fractions of mouse (ddY) tissues (about 1 g wet weight each) were 
isolated, suspended in 20 mM MOPS-Tris, pH. 7.0, 0.3 M sucrose, 5 mM EDTA, and 
protease inhibitors (pepstatin A, leupeptin, antipain, and chymostatin at 10 µg/ml 
each), and then homogenized.  The postnuclear supernatant was centrifuged at 
100,000 x g for 1 h, and the pellet was suspended in the same buffer and used as a 
protein sample after denaturation with buffer containing 1% SDS and 10% 
β-mercaptoethanol.  Samples (100 µg protein for human and 200 µg protein for 
mouse) were subjected to electrophoresis; Western blotting was performed 
subsequently as described (12). 
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Immunohistochemistry.  Human paraffin tissue sections were obtained from 
Biochain.  Immunohistochemical analysis was performed by the HRP-DAB method 
or indirect immunofluorescence microscopy as described (12).  The primary 
antibody treatment was performed at a concentration of 1 µg/ml or diluted x1000 in 
phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin for 1 h at 
room temperature.  Specimens were then examined under either an Olympus BX60 
microscope or an Olympus FV300 confocal laser microscope. 
 
Immunoelectron microscopy.  The pre-embedding silver enhancement 
immunogold method was used as described (12). Mice (ddY) were anesthetized with 
ether and then perfused intracardially with saline, followed by 4 % paraformaldehyde 
in 0.1 M phosphate buffer, pH 7.4.  The kidneys were isolated and washed with PBS.  
The organs were successively infiltrated with 30% sucrose in PBS, embedded in OTC 
compound (Sakura FineTek), sectioned at 6 mm thickness, and then mounted on 
silanized slides.  The sections were incubated in 0.1 M sodium phosphate buffer, pH 
7.4 containing 0.25 % saponin and 5 % bovine serum albumin (BSA) for 30 min and 
then in a blocking solution composed of 0.005% saponin, 10% BSA, 10% goat serum, 
and 0.1 % cold water fish gelatin (Sigma) for 30 min.  The sections were incubated 
with rabbit anti-mMATE1 antiserum diluted x1000 with the blocking solution 
overnight at 4 oC. After extensively washing the sections with the buffer containing 
0.005 % saponin, the sections were incubated in the blocking solution containing goat 
anti-rabbit IgG gold conjugate (gold particle diameter, 1.4 nm) for 2 h, washed six 
times with the buffer and then fixed with 1 % glutaraldehyde for 10 min.  After 
washing again, the gold labeling was intensified using a silver enhancement kit (HQ 
silver Nanoprobes) for 5 min at room temperature.  The sections were post-fixed 
with 0.5% OsO4 for 90 min.  Ultrathin sections were made and doubly stained with 
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uranyl acetate and lead citrate, and were examined under a Hitachi H-7100 electron 
microscope.  
 
Transport assay.  cDNA encoding hMATE1 was subcloned into the expression 
vector pcDNA3.1(+) (Invitrogen); this plasmid, pcDNA/hMATE1, was used to 
transfect HEK293 cells by the lipofection using TransIT reagent (Mirus). HEK293 
cells were grown in Dulbecco’s modified Eagle’s medium containing 10% fetal calf 
serum, penicillin, and streptomycin at 37 oC under 5% CO2 as describe (13).  
Twenty-four hours later, 10 µg each of pcDNA3.1/hMATE1 or the vector pcDNA3.1 
were used per transfection (1.5 x 106 cells on 10 cm dish).  The cells were grown for 
two days, harvested and suspended in transport assay medium containing 125 mM 
NaCl, 4.8 mM KCl, 5.6 mM D-glucose, 1.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM 
MgSO4, and 25 mM Tricine (pH 8.0).  Cells were incubated at 37 oC for 5 min; the 
transport assay was initiated by adding 50 µM radiolabeled TEA (5 KBq/assay) 
(PerkinElmer Life Science, Inc.) as described (13).  At appropriate times, aliquots of 
the mixture (200 µl) were filtered through 0.45 µm HA membrane filters (Millipore).  
Each filter was washed with ice-cold the medium and the radioactivity remaining on 
the filter was counted.  
 
Results and Discussion 
Gene organization and expression of human MATEs.  We searched for mammalian 
orthologues of bacterial MATE-type multidrug transporters in genomic databases.  
Upon screening the entire working draft of the human genome database, we found two 
genes encoding orthologues of bacterial MATE family.  The genes are located in 
tandem on chromosome 17, and the gene products are designated hMATE1 (accession 
number, NP-060712) and hMATE2 (accession number, NP-690872) (Fig. 1).  The 
deduced amino acid sequences of hMATE1 and hMATE2 exhibit 19.8 and 18.6% 
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identity to that of the NorM Na+/multidrug antiporter in Vibrio parahaemolyticus, a 
prototype of the MATE family (14) (Fig. 2A).  A hydropathy plot of hMATE1 predicts 
12 transmembrane domains (Fig. 2B).  Northern blot analysis of human tissues 
revealed that the gene encoding hMATE1 is primarily expressed in kidney, liver and 
skeletal muscle as a 4.1 kilobase (kb) transcript.  The expression in the other organs 
examined was below the detection limit (Fig. 3).  In contrast, the gene encoding 
hMATE2 is expressed as a 3.2 kb transcript in skeletal muscle, but not in kidney or liver 
(Fig. 3).   
 
Renal and hepatic localization of hMATE1.  We attempted to determine the 
expression and localization of hMATE1 as a candidate H+-coupled OC exporter at the 
protein level.  In Western blot analysis, site-specific polyclonal antibodies against the 
carboxyl terminal region of hMATE1 revealed the broad immunoreactive protein band 
of the expected size (~62 kDa) in human kidney membranes (Fig. 4A).  The 
preabsorbed antibodies did not yield the immunoreactivity (Fig. 4A).  Horseradish 
peroxidase (HRP)-DAB staining of human tissues showed that the antibodies 
predominantly immunostained the apical regions of the proximal and distal convoluted 
tubules of the kidney (Fig. 4B) and bile canaliculi (Fig. 4C, arrows).   
 
Expression and localization of mMATE1.  Because of the limited availability and 
quality of human samples for studies on the subcellular localization of MATE1, we 
investigated mouse homologues.  Genes encoding mouse homologues are located in 
tandem on chromosome 11 and the gene products are designated mMATE1 (accession 
number, AAH31436) and mMATE2 (accession number, XP_354611) (supplemental 
information, Fig. S1).  Their deduced amino acid sequences are 78.1 and 38.1% 
identical to that of their human counterparts, respectively (supplemental information, Fig. 
S2).  Northern blot analysis showed that gene encoding mMATE1 was predominantly 
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expressed in kidney, liver and heart as a 3.8 kb transcript, while that of mMATE2 was 
specifically expressed in testis as a 3.3 kb transcript (Fig. 5A).  In Western blot analysis, 
site-specific polyclonal antibodies for mMATE1 recognized a single polypeptide of 
about 53 kDa in the membranes of the kidney and liver, but the levels were low or below 
the detection limit in the other organs examined (Fig. 5B).  The HRP-DAB staining of 
a mouse kidney specimen revealed strong immunoreactivity in the apical region of 
cortical collecting ducts, proximal convoluted tubules (Fig. 5Ca), and thin limb of 
Henle’s loop (Fig. 5Cb).  Lower but distinct immunoreactivity was also observed in the 
distal convoluted tubules and glomerulus (Fig. 5Ca).  The localization of mMATE1 in 
the brush border membrane of proximal tubules was demonstrated by immunoelectron 
microscopy (Fig. 5D).  In the liver, mMATE1 is localized to the bile canaliculi (Fig. 
5E) and the apical region of the bile duct (Fig. 5F).  Together, these results 
demonstrated that MATE1 is predominantly found in the kidney and liver and is 
localized to the renal brush-border membrane and bile canaliculi, which agrees with that 
of H+/OC exchange activity (5-7). 
 
MATE1 mediates a H+-coupled electroneutral OC exchange.  To answer the 
question whether MATE1 exhibits H+-coupled OC transport, we measured the 
pH-dependent translocation of OCs across the plasma membranes of 
hMATE1-expressing HEK293 cells.  This approach allowed us to study the luminal 
efflux of OCs as a classical cellular uptake (13).  Upon expression of hMATE1, the 
protein predominantly localized at the plasma membrane region (Fig. 6A).  Some 
immunoractivity was also observed in the internal organelles.  The 
hMATE1-expressing cells exhibited time-dependent transport activity towards 
tetraethylammonium (TEA), a typical substrate for the H+-coupled OC exporter (2,15), 
while MOCK control cells did not (Fig. 6B).  Around 10 % mutated hMATE1 with the 
amino acid replacement E273Q (Glu273 to Gln), the counterpart of an essential amino 
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acid residue found in the bacterial NorM protein (16), also predominantly localized at 
the plasma membrane region but lacked detectable MATE1-dependent TEA transport 
activity (Fig. 6A, B).  The transport activity of the wild type was saturable, with a Km 
value for TEA of 220 µM (Fig. 6C).  The transport also showed pH dependence: the 
transport activity was lower at pH 6.0, increased at higher extracellular pH, and became 
maximal at around pH 8.0 – 8.5 (Fig. 6D).  Na+ was not required for transport activity 
(Fig. 6E).  The addition of 5 µM valinomycin in the presence of 65 mM KCl, which 
causes membrane depolarization, did not affect the TEA uptake, whereas 10 mM 
ammonium chloride inhibited the uptake by 60%.  In addition, 10 µM SF6847, a proton 
conductor, and 5 µM nigericin in the presence of KCl, which dissipates the pH gradient, 
decreased the uptake to the level of MOCK control (Fig. 6E).  Furthermore, TEA taken 
up by the cells was released upon an acute decrease in extracellular pH to 6.0 by means 
of acid pulse (Fig. 6F).  Together, these results indicated that hMATE1 mediated 
electroneutral H+/TEA exchange.  The pharmacology of the cis-inhibition of TEA 
transport was similar to that of renal H+-coupled OC export (1-7): it is strongly inhibited 
by cimetidine, quinidine or verapamil, less so by nicotine or choline, but not at all by 
organic anions such as p-aminohippurate (PAH) and uric acid (Table 1).  Similar 
pH-dependent transport was observed for MPP, another well-known substrate of the 
H+-coupled OC export (5); the Km and Vmax measured were 16 µM and 170 
pmol/min/mg protein, respectively.  Thus, MATE1 exhibited properties equivalent to 
those of the putative renal H+-coupled OC exporter.   
 
MATE1 as a OC exporter at the final step of excretion.  Based on this 
information, we conclude that MATE1 is the long searched for H+-coupled OC 
exporter that mediates the final step of excretion of OCs in kidney and liver (Fig. 7).  
Our findings contribute to the understanding of the transporters underlying the 
excretion of toxic OCs from the body:  OCs are taken up by organic cation 
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transporter 1 (OCT1) or OCT2 in the renal tubule cells and hepatocytes (4-7), and 
then excreted out of the cells through a co-operation between MATE1 and 
P-glycoprotein (Fig. 7).  The H+-coupled electroneutral transport should be 
important for permeation of OCs against potential difference across the plasma 
membrane.  The cis-inhibition experiment suggested that MATE1 recognized 
various kinds of physiological metabolites, such as corticosterone, as transport 
substrates (Table 1).  Since MATE1 and MATE2 were expressed in organs other 
than kidney and liver (Figs. 3, 5A), the function of mammalian MATE-type 
transporters may not be limited to the excretion of OCs, but may also act as 
molecular devices that allow homeostasis of electrolytes through efficient and 
regulated transportation of physiological metabolites of various sizes, structures, and 
hydrophobicity. 
       It is noteworthy that the MATE genes are among the approximately 80 genes 
located in the commonly deleted region in Smith-Magenis syndrome, a genomic 
disorder of chromosome 17p11.2 involving multiple congenital anomalies and mild 
mental retardation (17, 18). Most of the abnormalities in this syndrome are ascribed to 
hemizygosity for the retinoic acid induced 1 gene (RAI1).  The absence of short stature 
and visceral abnormalities in patients with point mutations in this gene suggest that 
hemizygosity for one or more other genes in this region explain these two features of 
the deletion syndrome(19, 20). Whether hemizygosity for hMATE1 (and also 
hMATE2) has any physiological significance or contributes to some of the features of 
this disorder remain to be determined. Nonetheless, the discovery of MATE1 provides a 
novel molecular target for studies on the interactions between exogenous toxins, drugs, 
and endogenous metabolites which could have a relationship to developmental and 
metabolic abnormalities. 
       Our results demonstrated the conservative nature of the MATE superfamily 
as a polyspecific OC exporter.  It is quite likely that the resistance to drugs and 
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endogenous toxic metabolites observed in plants can be attributed to their MATE 
homologues (21-23).  The MATE family is one of the fundamental OC exporters in 
nature and has a wide variety of roles through the excretion or sequestration of OCs 
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Figure 1.  Chromosomal localization and gene organization of hMATE1 and hMATE2.   
 
Figure 2.  Amino acid sequences of hMATE1 and hMATE2.  (A) The amino acid 
sequences of the proteins are aligned with that of NorM (14). Identical sequences are 
indicated by asterisks.  Predicted transmembrane regions are shaded.  (B) Putative 
secondary structure of hMATE1.  A glutamate residue (E273) that is essential for the 
transport activity is shown in red (16).   
 
Figure 3.  Expression of hMATE1 and hMATE2 in humans.  Northern blot analysis 
revealed that the expression of hMATE1 (upper) was predominantly in the kidney, liver 
and skeletal muscle, and that of hMATE2 (middle) was primarily in kidney.  Expression 
of G3PDH was also sown as a loading control (bottom).  
 
Figure 4.  MATE1 is a membrane protein localized to the apical membrane of renal 
tubule cells and bile canaliculi.  (A) Western blot analysis of hMATE1.  The 
antibodies recognized hMATE1 expressed in transfected HEK293 cells, and identified 
an immunological counterpart in human kidney tissue.  The pre-absorption test was 
performed by incubating the antibody with hMATE1 polypeptides (N461 – R546), (20 
µg/ml). Proteins from HEK293 cells transfected with pcDNA3.1 vector alone were used 
as the mock control. (B, C) Immunohistochemical detection of hMATE1 in kidney (B) 
and liver (C).  Sections of human samples were immunostained by the HRP method 
and counterstained with hematoxylin.  The insets show background staining with 
pre-immune serum.  PCT, proximal convoluted tubule; DCT, distal convoluted tubule. 
Bar = 100 µm. 
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Figure 5.  Expression and localization of mMATE1 and mMATE2. 
(A) Northern blotting revealed that the expression of mMATE1 was predominantly in the 
kidney and liver (left) and that of mMATE2 in testis (right).  kb, kilobases. (B) Western blot 
analysis indicated that the site specific antibody recognized the mMATE1 polypeptide in 
kidney and liver of mice (arrow).  Little immunoreactivity was observed in testis, and no 
mMATE1 was observed in membrane fractions prepared from other organs. (C) HRP-DAB 
immunostaining revealed that mMATE1 was localized to the renal cortex (a) and medulla (b). 
GL, glomerulus; PCT, proximal convoluted tubule; DCT, distal convoluted tubule; CCD, 
cortical collecting duct. Bar = 100 µm. (D) In immunoelectron micrographs, mMATE1 was 
observed in the apical membrane of renal proximal tubules.  BBM, brush border 
membrane; BM, basal membrane; M, mitochondrion; L, lumen.  Bar = 1 µm.  (E, F)  In 
liver, mMATE1 (green color) was localized to the canalicular membrane (E) and the apical 
membrane of the bile duct (F) as revealed by indirect immunofluorescent microscopy. BD, 
interlobular bile duct; HPV, hepatic portal vein.  Pictures merged with Nomarski images are 
shown.  Bar = 10 µm.  
 
Figure 6.  MATE1 mediates electroneutral H+/TEA exchange.  (A) Presence of wild type 
and E273Q mutated hMATE1 in HEK293 cells, as revealed by indirect immunofluorescence 
microscopy.  No immunoreactivity was observed in a mock control, which was from 
HEK293 cells transfected with pcDNA3.1 vector alone.  (B) Time course of TEA (50 µM) 
uptake at pH 8.0 by HEK293 cells expressing hMATE1, the E273Q mutant or a mock 
control. (C) Dose-dependence of TEA uptake at pH 8.0.  The values obtained at the 
indicated concentrations from the mock control cells were subtracted from the corresponding 
values obtained from cells expressing wild type hMATE1.  (D) pH dependence of TEA 
uptake.  HEK293 cells expressing wild type hMATE or a mock control were incubated at 
the indicated pH and TEA uptake was then measured.  (E) The effect of Na+ on TEA 
uptake was examined in buffer containing 65 mM KCl and 65 mM NaCl (control) or in 
 17 
buffer containing 130 mM KCl (Na+ free).  The requirement of a membrane potential or pH 
gradient for TEA uptake was also examined at pH 8.0 in the absence or presence of 10 mM 
ammonium chloride, 5 mM nigericin, 10 µM SF6847 or 5 µM valinomycin in buffer 
containing 65 mM KCl and 65 mM NaCl (control).  (F) pH-dependent extrusion of TEA.  
hMATE1-expressing cells were incubated with 50 µM radiolabeled TEA as in Fig. 2B for 10 
min.  Then, the cells were transferred to buffer with the indicated pH (time = 0) and 
incubated for a further 10 min and the remaining radioactivity then assayed.  Error bars are 
the standard deviation of three samples. 
 
Figure 7.  MATE1 is a polyspecific OC exporter at the final step of OC excretion.  
In liver, hepatocytes take up OCs at the sinusoidal membrane through an organic cation 
transporter 1 (OCT1), and then extrude them across the bile canaliculi by a combination of 
MATE1 and a multidrug resistance protein 1 (MDR1).  In kidney, OCs are taken up by the 
renal tubular cells mainly through an organic cation transporter 2 (OCT2) located in the 
basolateral membrane and secreted by different transporters including MATE1, MDR1, and 
OCTN2 (OCT isoform).    
 
Supplemental Figure Legends  
 
Figure S1.  Chromosomal localization and gene organization of mMATE1 and mMATE2.   
 
Figure S2.  Amino acid sequences of mMATE1 and mMATE2.  The amino acid sequences 
of the proteins are aligned with that of hMATE1. Identical sequences are indicated by 
asterisks.  Predicted transmembrane regions are shaded.  An essential Glu residue for 
transport activity in hMATE1 is shown in red (16).   
